Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update
- Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer patients treated with BPX-601 in Phase 1/2 study - - Favorable safety profile observed in... | March 24, 2022